Please assess the completion status of the following clinical trial:

Trial Title: Peri-orbital and Peri-oral Wrinkle Reduction Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 30 to 75 years.~* Subject in good health.~* BMI\<25~* Fitzpatrick wrinkle score of 3-7 in the peri-orbital and peri-oral areas.~* Moderate skin laxity in the peri-orbital area contributing to rhytids as assessed by the investigator.~* Understands and accepts the obligation not to undergo any other procedures, including neurotoxin and filler treatments, on the face through the follow-up period.~* Willingness to refrain from use of aspirin, Ibuprofen, Naproxen or any other NSAID, and Vitamin E in the 2 weeks prior to each study treatment.~* Willingness and ability to continue with their current daily skin care routine, with the exception of any use of products containing glycolic acid, for the duration of the study.~* Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.~* Subjects of childbearing potential must have a negative urine pregnancy test result and must not be lactating at the Screening Visit and be willing and able to use an acceptable method of birth control during the study.~* Absence of physical or psychological conditions unacceptable to the investigator.~* Willingness and ability to provide written consent for study-required photography and adherence to photography procedures (i.e., removal of jewelry and makeup).~* Willingness and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedure.~Exclusion Criteria:~* Presence of an active systemic or local skin disease that may affect wound healing.~* BMI equal to or greater than 25~* Severe solar elastosis.~* Excessive subcutaneous fat in the area(s) to be treated.~* Mild or severe skin laxity on the area(s) to be treated.~* Significant scarring in the area(s) to be treated.~* Open wounds or lesions in the area(s) to be treated.~* Severe or cystic acne on the area(s) to be treated.~* Active implantables (e.g., pacemakers or defibrillators) or metallic implants in the treatment area.~* Inability to understand the protocol or to give informed consent.~* Microdermabrasion, or prescription level glycolic acid treatment to the treatment area(s) within 4 weeks prior to study participation or during the study.~* Marked asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin in the area(s) to be treated.~* History of chronic drug or alcohol abuse.~* History of autoimmune disease.~* History of Bell's Palsy or epilepsy.~* History of diabetes.~* Has a known allergy, or a known history of sensitivity, to lidocaine, tetracaine, para-aminobenzoic acid (PABA).~* Concomitant therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study device.~* Subjects who anticipate the need for surgery or overnight hospitalization during the study.~* Subjects who, in the investigator's opinion, have a history of poor cooperation, noncompliance with medical treatment, or unreliability.~* Concurrent enrollment in any study involving the use of investigational devices or drugs.~* Current smoker or history of smoking in the last five years.~* History of the following cosmetic treatments in the area(s) to be treated:~  1. Skin tightening procedure within the past year;~ 2. Injectable fillers of any type within the past 12 or 24 months, depending on type;~ 3. Neurotoxins within the past six months;~ 4. Ablative resurfacing laser treatment;~ 5. Nonablative, rejuvenative laser or light treatment within the past six months;~ 6. Surgical dermabrasion or deep facial peels;~ 7. Facelift, blepharoplasty, or browlift within the past 2 years; or~ 8. Any history of contour threads.~* History of using the following prescription medications:~  1. Accutane or other systemic retinoids within the past six months;~ 2. Topical Retinoids within the past four weeks;~ 3. Antiplatelet agents/Anticoagulants;~ 4. Psychiatric drugs that in the investigators opinion would impair the subject from understanding the protocol requirements or understanding and signing the informed consent.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Ulthera® System Treatment (Type: EXPERIMENTAL): Ulthera® System treatment of the peri-orbital and peri-oral regions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy